Worth Asset Management’s AGF US Market Neutral Anti-Beta Fund BTAL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-30,472
Closed -$425K 216
2026
Q1
$425K Buy
30,472
+5,190
+21% +$72.8K 0.16% 121
2025
Q4
$364K Buy
+25,282
New +$380K 0.15% 98
2024
Q4
Sell
-41,346
Closed -$810K 144
2024
Q3
$810K Buy
41,346
+5,760
+16% +$115K 0.44% 55
2024
Q2
$698K Sell
35,586
-4,327
-11% -$82.1K 0.41% 51
2024
Q1
$719K Sell
39,913
-11,681
-23% -$212K 0.44% 49
2023
Q4
$875K Buy
51,594
+10,792
+26% +$214K 0.63% 44
2023
Q3
$810K Buy
40,802
+35,405
+656% +$671K 0.66% 48
2023
Q2
$101K Sell
5,397
-105,860
-95% -$2.13M 0.08% 139
2023
Q1
$2.27M Sell
111,257
-45,836
-29% -$922K 1.72% 8
2022
Q4
$3.33M Buy
157,093
+72,045
+85% +$1.49M 2.32% 7
2022
Q3
$1.73M Sell
85,048
-18,894
-18% -$376K 1.27% 16
2022
Q2
$2.26M Buy
103,942
+48,709
+88% +$983K 1.55% 12
2022
Q1
$1.15M Buy
+55,233
New +$1.02M 0.75% 31

Other funds holding BTAL

Worth Asset Management's BTAL Position: Q2 2026 in Review

Worth Asset Management sold out of AGF US Market Neutral Anti-Beta Fund (BTAL) in Q2 2026, closing a stake of 30,472 shares — an estimated $425K sold.

Worth Asset Management first reported a position in BTAL in Q1 2022 and held it in 13 quarters. The position peaked at $3.33M in Q4 2022. 6 funds tracked by Wall St. Rank hold BTAL as of Q2 2026.

  • Worth Asset Management reported no remaining AGF US Market Neutral Anti-Beta Fund position as of Q2 2026 after selling out during the quarter.
  • Worth Asset Management sold 30,472 AGF US Market Neutral Anti-Beta Fund shares in Q2 2026, an estimated $425K.
  • Worth Asset Management first reported a position in AGF US Market Neutral Anti-Beta Fund in Q1 2022 and held it in 13 quarters.
  • Worth Asset Management's AGF US Market Neutral Anti-Beta Fund position peaked at $3.33M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held AGF US Market Neutral Anti-Beta Fund as of Q2 2026.

Based on Worth Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.